心功能、难治性腹水与非选择性β受体阻滞剂对等待肝移植肝硬化患者结局的影响
左室每搏作功指数(LVSWI)在难治性腹水患者中显著更低;校正血钠和MELD评分后,难治性腹水及LVSWI<64.1 g-m/m2时使用NSBBs与等待名单死亡率独立相关,提示心功能受损者使用NSBBs可能有害。
要点
- 难治性腹水患者LVSWI显著更低,提示心功能受损更常见。
- LVSWI<64.1 g-m/m2时使用NSBBs与等待名单死亡率增加独立相关。
- 终末期肝硬化评估中应关注整体心功能对预后的影响。
核心结论
- 心功能受损在难治性腹水患者中更常见,且NSBBs对心功能受损的肝硬化患者可能有害。
- 研究结果强调终末期肝硬化患者心功能的预后价值。
研究设计与样本
- 研究纳入1999至2014年间连续评估肝移植的584例肝硬化患者。
- 心功能以左室每搏作功指数(LVSWI)评估,采用竞争风险分析探讨未行肝移植的等待名单死亡率。
主要发现
- 难治性腹水患者的LVSWI显著更低。
- 多因素竞争风险分析显示,全人群中难治性腹水、NSBBs及LVSWI与等待名单死亡率相关,且NSBBs与LVSWI存在统计学显著交互作用。
- LVSWI最具判别力的界值为64.1 g-m/m2。
- 最终模型中,校正血钠和MELD评分后,难治性腹水(亚分布风险比1.52;95%CI 1.01-2.28;p=0.0083)及LVSWI<64.1 g-m/m2时使用NSBBs(亚分布风险比1.96;95%CI 1.32-2.90;p=0.0009)与等待名单死亡率显著相关。
关键数值与推荐
- LVSWI最具判别力的界值为64.1 g-m/m2。
- 难治性腹水与等待名单死亡率的亚分布风险比为1.52(95%CI 1.01-2.28;p=0.0083)。
- LVSWI<64.1 g-m/m2时使用NSBBs与等待名单死亡率的亚分布风险比为1.96(95%CI 1.32-2.90;p=0.0009)。
临床怎么用
- 对等待肝移植的肝硬化患者,尤其合并难治性腹水者,应评估整体心功能。
- 心功能受损(LVSWI<64.1 g-m/m2)的患者使用NSBBs需谨慎权衡等待名单死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Whether non-selective beta blockers (NSBBs) are deleterious in patients with end-stage cirrhosis and refractory ascites has been widely debated. We hypothesized that only the subset of patients on the liver transplant waiting list who had impaired cardiac performance would be at increased risk of mortality if receiving NSBBs. METHODS: This study included 584 consecutive patients with cirrhosis evaluated for transplantation between 1999 and 2014. All patients had right heart catheterization with hemodynamic measurements at evaluation. Fifty percent received NSBBs. Refractory ascites was present in 33%. Cardiac performance was assessed by left ventricular stroke work index (LVSWI). Waiting list mortality without liver transplantation was explored using competing risk analysis. RESULTS: LVSWI was significantly lower in patients with refractory ascites. In multivariate analysis using competing risk, refractory ascites, NSBBs and LVSWI were associated with waiting list mortality in the whole population, with a statistically significant interaction between NSBBs and LVSWI. The most discriminant value of LVSWI was 64.1 g-m/m2. In the final model, refractory ascites (subdistribution hazard ratio 1.52; 95% CI1.01-2.28; p = 0.0083) and treatment by NSBBs with LVSWI <64.1 g-m/m2 (subdistribution hazard ratio 1.96; 95% CI 1.32-2.90; p = 0.0009) were significantly associated with waiting list mortality, taking into account serum sodium and the model for end-stage liver disease score. CONCLUSIONS: This study suggests that compromised cardiac performance is more common in patients with refractory ascites and that NSBBs are deleterious in cirrhotic patients with compromised cardiac performance. These results highlight the prognostic value of cardiac function in patients with end-stage cirrhosis. LAY SUMMARY: There are still controversies concerning the impact of non-selective beta blockers on outcomes in patients with decompensated cirrhosis, especially in those with refractory ascites. In this study of 584 cirrhotic patients evaluated for liver transplantation, who underwent right heart catheterization, we have shown that global cardiac performance measured by left ventricular stroke work index is lower in patients with refractory ascites. Administration of non-selective beta blockers in patients with compromised cardiac performance may increase waiting list mortality. These results highlight the prognostic value of global cardiac performance in patients with end-stage cirrhosis.
引用
- Giannelli V, Roux O, Laouénan C, et al. Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation. J Hepatol. 2019. PMID: 31622697. doi:10.1016/j.jhep.2019.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。